Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D
Branded GLP-1s carry rigorous regulatory approval, established dosing protocols and extensive safety databases from clinical trials
Niacinamide-specific side effects At the low doses used in compounded formulations (2 mg per mL), niacinamide side effects are extremely unlikely
Carnitine plays an important role in energy production
Weight Loss Outcomes with GLP-1 and GIP Drugs Speed of Weight Loss with GLP-1 Drugs Patients using GLP-1 drugs often begin to see weight loss within the first few weeks of treatment
The Precision Peptide Genetic Test maps 49 genes and 58 variants across 14 health pathways including weight-management insights and the GIPR rs1800437 variant
US$ 22.53
US$ 23.74
US$ 29.10
US$ 26.85
